MICHELLE EYLER: Open Payments
NPI 1376138446 · LA JOLLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$457 in 19 payments from 9 companies in 2025. Trend: 2023 $180 · 2024 $465 · 2025 $457
Food & beverage: $457
| Company | Payments | Amount |
|---|---|---|
| Verity Pharmaceuticals Inc. | 3 | $96 |
| Novo Nordisk Inc | 3 | $77 |
| Lilly USA, LLC | 3 | $73 |
| Novartis Pharmaceuticals Corporation | 3 | $64 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Exact Sciences Corporation | 1 | $16 |
Products named: Tlando, LEQVIO, XIFAXAN, MOUNJARO, Wegovy, Saxenda, REXULTI, LUMRYZ.
Industry payments across CA — which companies pay providers there.
